Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis [0.03%]
阿片类药物使用与重大抑郁症和焦虑及压力相关障碍风险之间的因果关系：孟德尔随机化分析研究
Daniel B Rosoff,George Davey Smith,Falk W Lohoff
Daniel B Rosoff
Importance: Growing evidence suggests that prescription opioid use affects depression and anxiety disorders; however, observational studies are subject to confounding, making causal inference and determining the direction...
Effect of Cognitive Bias Modification on Early Relapse Among Adults Undergoing Inpatient Alcohol Withdrawal Treatment: A Randomized Clinical Trial [0.03%]
认知偏差修正对住院酒精戒断成人患者早期复发的影响：一项随机临床试验
Victoria Manning,Joshua B B Garfield,Petra K Staiger et al.
Victoria Manning et al.
Importance: More than half of patients with alcohol use disorder who receive inpatient withdrawal treatment relapse within weeks of discharge, hampering subsequent uptake and effectiveness of psychological and pharmacolog...
Randomized Controlled Trial
JAMA psychiatry. 2021 Feb 1;78(2):133-140. DOI:10.1001/jamapsychiatry.2020.3446 2021
Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia [0.03%]
采用遗传学方法澄清大麻使用与精神分裂症风险之间关系的性质
Nathan A Gillespie,Kenneth S Kendler
Nathan A Gillespie
Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial [0.03%]
一项开放性临床试验中4周全谱高大麻二酚治疗后的尿液四氢大麻酚变化情况
M Kathryn Dahlgren,Kelly A Sagar,Ashley M Lambros et al.
M Kathryn Dahlgren et al.
This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.
Clinical Trial
JAMA psychiatry. 2021 Mar 1;78(3):335-337. DOI:10.1001/jamapsychiatry.2020.3567 2021
Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis? [0.03%]
裸盖菇素辅助支持性心理治疗在重度抑郁症治疗中的前景何去何从？
Charles F Reynolds rd
Charles F Reynolds rd
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial [0.03%]
裸盖菇素辅助治疗对抑郁症的效果：随机临床试验
Alan K Davis,Frederick S Barrett,Darrick G May et al.
Alan K Davis et al.
Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with p...
Randomized Controlled Trial
JAMA psychiatry. 2021 May 1;78(5):481-489. DOI:10.1001/jamapsychiatry.2020.3285 2021
Johan Ormel,Michael VonKorff
Johan Ormel
Harnessing Collaborative Care to Meet Mental Health Demands in the Era of COVID-19 [0.03%]
利用协作护理以满足COVID-19时代的心理健康需求
Andrew D Carlo,Brian S Barnett,Jürgen Unützer
Andrew D Carlo
The COVID-19 era presents unprecedented mental health treatment access challenges. This Viewpoint outlines why Collaborative Care, an extensively evidence-based model for integrated care, is the most promising strategy to meet this critical...
Update to Open Access Status [0.03%]
开放获取状态更新
Published Erratum
JAMA psychiatry. 2020 Dec 1;77(12):1310. DOI:10.1001/jamapsychiatry.2020.3534 2020